Thrombocytopenia
Angiomax label expansion approved to include patients with or at risk of HIT/HITTS undergoing PCI
Published in Medical Letter on the CDC and FDA, January 1st, 2006
HIT/HITTS is a complication of heparin administration that can have devastating clinical consequences for patients, including limb amputation, renal failure, and even death.
"We hope to continue demonstrating that replacing heparin with Angiomax leads to better outcomes, particularly in high risk patients, such as those with HIT/HITTS," said John Kelley, The Medicines Co.'s...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Bacterial Diarrhea
People with HIV infection are at increased risk for bacterial diarrhea - HIV/AIDS Epidemiology
Diversity among Asians and Pacific Islanders in U.S. must be considered to prevent HIV/AIDS - Malaria Prevention
Long-lasting insecticidal net is better than conventional nets for malaria protection - Malaria Risk Factors
Measles vaccination does not increase risk of malaria in western Kenya - Tuberculosis Vaccine
Sindbis virus-based DNA vaccine protects against M. tuberculosis - Back Pain
U.S. FDA approves minimally invasive system to treat common degenerative spine disorder - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
